Agenus Inc
General ticker "AGEN" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $70.0M
Agenus Inc does not follow the US Stock Market performance with the rate: -26.5%.
Estimated limits based on current volatility of 3.8%: low 2.67$, high 2.88$
Factors to consider:
- Current price 68.7% below estimated low
- Earnings for 18 months up through Q2 (+1 year) are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2022-12-31 to 2024-12-30
- 2022-12-31 to 2023-12-31 estimated range: [15.42$, 43.95$]
- 2023-12-31 to 2024-12-30 estimated range: [8.70$, 25.76$]
Financial Metrics affecting the AGEN estimates:
- Negative: Non-GAAP EPS, $ of -15.80 <= 0.10
- Negative: Operating profit margin, % of -64.48 <= 1.03
- Negative: Operating cash flow per share per price, % of -19.45 <= 2.35
- Negative: negative Net income
- Negative: Interest expense per share, $ of 4.39 > 0.74
- Negative: Industry operating cash flow per share per price (median), % of -21.66 <= 3.85
- Positive: -3.48 < Investing cash flow per share, $ of -2.39
Short-term AGEN quotes
Long-term AGEN plot with estimates
Financial data
| YTD | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|
| Operating Revenue | $86.95MM | $284.18MM | $98.84MM |
| Operating Expenses | $204.18MM | $258.44MM | $278.27MM |
| Operating Income | $-117.23MM | $25.75MM | $-179.43MM |
| Non-Operating Income | $-65.66MM | $-54.47MM | $-51.23MM |
| Interest Expense | $61.08MM | $65.72MM | $61.86MM |
| R&D Expense | $142.62MM | $178.61MM | $16.98MM |
| Income(Loss) | $-182.89MM | $-28.72MM | $-230.66MM |
| Profit(Loss) | $-182.89MM | $-28.72MM | $-230.66MM |
| Stockholders Equity | $-203.67MM | $34.44MM | $-61.28MM |
| Inventory | $10.75MM | $20.36MM | $13.83MM |
| Assets | $214.51MM | $465.96MM | $413.56MM |
| Operating Cash Flow | $-139.10MM | $10.14MM | $-175.37MM |
| Capital expenditure | $3.47MM | $33.81MM | $53.06MM |
| Investing Cash Flow | $-4.44MM | $-43.15MM | $-33.61MM |
| Financing Cash Flow | $183.85MM | $225.26MM | $95.83MM |
| Earnings Per Share* | $-27.84 | $-8.27 | $-19.27 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.